<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Risk of severe orthostatic hypotension. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS" code="C0-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Increased risk of orthostatic hypotension </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG1>
<DRUG2>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG2>
<DESCRIPTION>Risk of orthostatic hypotension, especially in older patients

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with doxazosin</COMMENT>
</INTERACTION>
</INTERACTIONS>
